Cited by 170Alzheimer's disease research and treatmentsNeurogenesis and neuroplasticity mechanismsNeuroinflammation and Neurodegeneration Mechanisms

Neuroplasticity in Alzheimer's disease

Open access
Teter, Bruce, Ashford, J. Wesson·2002·Journal of Neuroscience Research

Abstract

Ramon y Cajal proclaimed in 1928 that “once development was ended, the founts of growth and regeneration of the axons and dendrites dried up irrevocably. In the adult centers the nerve paths are something fixed, ended and immutable. Everything must die, nothing may be regenerated. It is for the science of the future to change, if possible, this harsh decree.” (Ramon y Cajal, 1928). In large part, despite the extensive knowledge gained since then, the latter directive has not yet been achieved by ‘modern’ science. Although we know now that Ramon y Cajal's observation on CNS plasticity is largely true (for lower brain and primary cortical structures), there are mechanisms for recovery from CNS injury. These mechanisms, however, may contribute to the vulnerability to neurodegenerative disease. They may also be exploited therapeutically to help alleviate the suffering from neurodegenerative conditions. Published 2002 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jnr.10441

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aβ aggregates bind to neuronal and glial membranes, disrupting membrane integrity and receptor function.

    “Mechanistically, Aβ aggregates bind to neuronal and glial membranes, disrupting membrane integrity and receptor function.”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [86]

    Section 5.4 (page unavailable) says Aβ can alter membrane potential and synaptic transmission, supporting a general effect on neuronal function. It does not say that Aβ aggregates bind neuronal and glial membranes or that they disrupt membrane integrity or receptor function; those specific mechanisms are unsupported. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Early alterations in connectivity and plasticity, detectable through functional imaging or electrophysiological biomarkers, may precede clinical symptoms and represent a window of opportunity for intervention.

    “Moreover, early alterations in connectivity and plasticity, detectable through functional imaging or electrophysiological biomarkers, may precede clinical symptoms and represent a window of opportunity for intervention [86, 87].”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [86]

    Section 3.3 describes altered plasticity-related proteins in early Alzheimer’s disease, and Section 10.1 discusses therapies targeting plasticity. The paper does not establish that connectivity or plasticity changes detectable by functional imaging or electrophysiological biomarkers precede clinical symptoms, or that such detection defines an intervention window. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Aβ triggers maladaptive changes including activation of microglia and astrocytes with release of inflammatory cytokines, impaired glutamate clearance leading to excitotoxicity, and aberrant NMDA receptor hyperactivation.

    “This triggers a cascade of maladaptive changes, such as (i) activation of microglia and astrocytes with release of inflammatory cytokines, (ii) impaired glutamate clearance leading to excitotoxicity, and (iii) aberrant NMDA receptor hyperactivation [86].”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [86]

    Section 5.4 (page unavailable) describes Aβ as neurotoxic and disruptive to synaptic activity. Section 2.4 (page unavailable) says activated microglia and astrocytes can inhibit neurite outgrowth and that glia secrete cytokines. Neither passage establishes that Aβ activates those cells to release inflammatory cytokines, impairs glutamate clearance, or hyperactivates NMDA receptors. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. Ashford JW, Mattson M, Kumar V. 1998a. Neurobiological systems dis- rupted by Alzheimer's disease and molecular biological theories of vul- nerability. In: Kumar V, Eisdorer C, editors. Advances in the diagnosis and treatment of Alzheimer's disease. New York: Springer.
  2. Braak H, Braak E. 1988. Chapter 2. In: Histology and histopathology of the aging brain. Basel: Karger.
  3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
  4. Cotman CW, Cummings BJ, Whitson JS. 1991. The role of misdirected plasticity in plaque biogenesis and Alzheimer's disease pathology. In: Hefti F, Brachet B, Christen WY, editors. Growth factors and Alzheimer's disease. Berlin: Springer-Verlag. p 222-233.
  5. Cotman CW, Cummings BJ, Pike CJ. 1993. Molecular cascades in adaptive versus pathological plasticity. New York: Raven Press.
  6. De Vreese LP, Neri M, Fioravanti M, Belloi L, Zanetti O. 2001. Memory rehabilitation in Alzheimer's disease: a review of progress. Int J Geriatr Psychiatry 16:794 -809.
  7. Geula C, Mesulam MM. 1999. Cholinergic systems in Alzheimer's disease. In: Terry RD, Katzman R, Sisodia SS, Bick KL, editors. Alzheimer's disease. Philadelphia: Lippincott, Williams & Wilkins. p 269 -292.
  8. Hebb DO. 1949. The organization of behaviour. New York: Wiley.
  9. Hof PR, Morrison JH. 1994. The cellular basis of cortical disconnection in Alzheimer's disease and related dementing conditions. In: Terry RD, Katzman R, Bick KL, editors. The cellular basis of cortical disconnection in Alzheimer's disease and related dementing conditions. New York: Raven Press. p 197-229.
  10. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St. George-Hyslop P, Westaway D. 2000. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408:979 -982.
  11. Kosik KS. 1991. The neuritic dystrophy of Alzheimer's disease: degenera- tion or regeneration? In: Hefti F, Brachet B, Christen WY, editors. Growth factors and Alzheimer's disease. New York: Springer-Verlag. p 234 -240.
  12. Masliah E, Mallory M, Alford M, Ge N, Mucke L. 1995b. Abnormal synaptic regeneration in hAPP695 transgenic and ApoE knockout mice. In: Iqbal K, Mortimer J, Winblad B, Wisniewski HM, editors. Research advances in Alzheimer's disease and related disorders. Chichester: Wiley. p 405-414.
  13. Masliah E, Mallory M, Alford M, Veinbergs I, Roses AD. 1995d. Apoli- poprotein E role in maintaining the integrity of the aging central nervous system. In: Christian Y, Roses AD, editors. Apolipoprotein E and Alz- heimer's disease. Berlin Heidelberg: Springer-Verlag.
  14. McEwen BS. 2001. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 91:2785-2801.
  15. Rabchevsky AG. 2002. Influences of activated microglia/brain macro- phages on spinal cord injury and regeneration. In: Streit WJ, editor. Microglia in the regenerating and degenerating central nervous system. New York: Springer-Verlag. p 209 -226.
  16. Reier PJ, Stensaas LJ, Guth L. 1983. The astrocytes scar as an impediment of regeneration in central nervous system. In: Kan CG, Bunge RP, Reier PJ, editors. Spinal cord reconstruction. New York: Raven Press. p 163-195.
  17. Roses AD, Saunders AM, Alberts MA, Strittmatter WJ, Schmechel D, Gorder E, Pericak-Vance MA. 1995. Apolipoprotein E E4 allele and risk of dementia. JAMA 273:374 -375.
  18. Roses AD, Einstein G, Gilbert J, Goedert M, Han SH, Huang D, Hulette C, Masliah E, Pericak-Vance MA, Saunders AM, Schmechel DE, Stritt- matter WJ, Weisgraber KH, Xi PT. 1996. Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Ann N Y Acad Sci 777:147-157.
  19. Roses AD, Saunders AM. 1997. Lipid metabolism in the brain: a truly undeveloped science. In: de la Torre JC, Hachinski V, editors. Cerebro- vascular pathology in Alzheimer's disease. New York: New York Acad- emy of Sciences. p 208.
  20. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I. 1998. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord 9(Suppl):36 -43.
  21. Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, Wallace DM, Strittmatter WJ, Roses AD. 2000. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochim Biophys Acta 1502:85-94.
  22. Terry RD, Masliah E, Hansen LA. 1994. Structural basis of the cognitive alterations in Alzheimer's disease. In: Terry RD, Katzman R, Bick K, editors. Alzheimer disease. New York: Raven Press. p 179 -196.
  23. Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M. 2001a. Mini review: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 142:969 -973.

Cited by

Sorted by citations

Authors
Teter, B., & Ashford, J. W.
Affiliations
  • University of California, Los Angeles (US)
  • University of Kentucky (US)
Venue
Journal of Neuroscience Research
Publisher
Wiley
Published
2002-10-18
Volume
70
Issue
3
Pages
402-437
ISSN
  • 0360-4012 (ISSN-L)
  • 1097-4547
OpenAlex
W1985802666
Cited by
170
References
40
Citations by year
2026: 3 · 2025: 4 · 2024: 7 · 2023: 9 · 2022: 28 · 2021: 4 · 2019: 20 · 2018: 3 · 2017: 5 · 2015: 7 · 2014: 4 · 2013: 4 · 2012: 7
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (K01AG000962)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
neuroplasticity, Alzheimer's disease, neurodegeneration, central nervous system injury
MeSH terms
Alzheimer Disease, Animals, Apolipoproteins E, Brain, Estrogens, Humans, Neural Pathways, Neuronal Plasticity, Amyloid beta-Peptides, tau Proteins, Growth Cones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review